Loading patent…
AssigneeThe Trustees of Columbia University in the City of New York
InventorIlyas Washington
Estimating the term…
Methods of retarding formation of a lipofuscin pigment in the retina and of treating or ameliorating the effects of a disease characterized by an accumulation of a lipofuscin pigment in a retina are provided. These methods include the step of administering to a patient in need thereof a substituted C20-retinoid in an amount sufficient to reduce accumulation of a lipofuscin pigment in the retina. Further provided are methods of retarding formation of A2E and/or ATR-dimer by replacing an all-frans-retinal (ATR) substrate with a C20-D3-retinal substrate under conditions sufficient to impede the formation of A2E. Compositions for retarding formation of a lipofuscin pigment in the retina containing a substituted C20-retinoid and a pharmaceutically acceptable carrier are also provided.
A method of retarding formation of a lipofuscin pigment in the retina comprising administering to a patient in need thereof a substituted C20-retinoid in an amount sufficient to reduce accumulation of a lipofuscin pigment in the retina.
A method of treating or ameliorating the effects of a disease characterized by an accumulation of a lipofuscin pigment in a retina comprising administering to a patient in need thereof a substituted C20-retinoid in an amount sufficient to reduce accumulation of a lipofuscin pigment in the retina.
A composition for retarding formation of a lipofuscin pigment in the retina comprising a substituted C20-retinoid and pharmaceutically acceptable carrier.
A method of retarding formation of a lipofuscin pigment selected from the group consisting of an A2E, an ATR dimer, and combinations thereof, the method comprising replacing an all-trans-retinal (ATR) substrate with a C20-D3-retinoid substrate under conditions sufficient to impede formation of A2E, ATR dimer, or both A2E and ATR dimer.
A composition comprising a pharmaceutically acceptable carrier and a compound according to formula I:
A method of retarding formation of A2E in a patient comprising replacing an all-trans-retinal (ATR) substrate with a substituted C20-D3-retinoid substrate in a patient under conditions sufficient to impede the formation of A2E.
Dependencies are inferred from the claim text.